Last reviewed · How we verify
review medication
At a glance
| Generic name | review medication |
|---|---|
| Also known as | person centered review medication |
| Sponsor | Parc Sanitari Pere Virgili |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Population Health Approach to Optimizing Medications in Older Adults (NA)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- Neurobiology of Suicide (PHASE2)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (PHASE2)
- Effects of Diabetic Educational Intervention and Dietary Supplements on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Management Among Adult Individuals With Painful Diabetic Peripheral Neuropathy. (NA)
- A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 (PHASE1)
- INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- review medication CI brief — competitive landscape report
- review medication updates RSS · CI watch RSS
- Parc Sanitari Pere Virgili portfolio CI